Submental Fat
Conditions
Keywords
submental, Salmeterol Xinafoate, LIPO-202, bulge
Brief summary
Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a Moderate Bulge or Large Bulge in the submental fat (on Patient-Reported Submental Bulging Scale \[PR-SBS\] and Clinician-Reported Submental Bulging Scale \[CR-SBS\]) will be recruited for this study.
Detailed description
Potential subjects will present and complete the Screening Visit. All qualifying subjects will be randomized to one of three treatment groups and treated with up to 30 subcutaneous injections of the assigned study drug into submental fat, once a week for 8 weeks. Upon completion of treatment visits, subject will return to the clinic for a follow-up visit and end of study visit, one and four weeks after the last treatment. The number and pattern of injections will be based on the area (cm x cm) of submental fat at baseline. At each visit the subjects will also undergo an examination of the treatment area, collection of vital signs and questioning about possible adverse events (AEs). The study consists of 11 visits: a Screening Visit, eight Treatment Visits, a Follow up Visit and an End of Study Visit.
Interventions
DRUGLIPO-202
DRUGPlacebo for LIPO-202
Lyophile manufactured to mimic LIPO-202 lyophile.
Sponsors
Neothetics, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Healthy males or non-pregnant females; 2. Capable of providing written, informed consent; and , 3. Have submental bulging that is evaluated by the Investigator as Moderate or Large.
Exclusion criteria
1. History of prior treatment to reduce submental bulging; 2. History of derm fillers, chemical peels, or laser or radio frequency procedures in the neck/chin area within 12 months of screening; 3. History of botulinum toxin in the neck/chin area within 6 months of screening; 4. Any skin conditions (including, but not limited to: skin infections, psoriasis, eczema, keloids, tattoos or hypertrophic or tethered scars) or history of trauma in the treatment area that may affect study procedures; 5. A score of 4 (Extreme Laxity) on the Skin Laxity Assessment Scale at Visit 1 (Screening); 6. Any known hypersensitivity to the study drug and/or any of the components; 7. Prior or current enrollment in any Lithera/Neothetics sponsored LIPO-102/LIPO-202 study; 8. Concurrently enrolled in another investigational drug or device study or used any experimental or investigational drug or device within 30 days of screening; 9. Female subject who is pregnant or lactating; 10. Any medical condition that in the opinion of the Investigator might complicate study procedures or assessments or jeopardize the subject's safety, including, but not limited to: 1. any bleeding or connective tissue disorders; 2. any clinically significant kidney or liver disease; 3. any untreated thyroid disease; 4. asthma, COPD, diabetes (Type I and II) or cardiovascular disease 5. history of major surgery within 30 days prior to randomization, or planned surgery during the study period; 11. Used drugs with anticoagulant activity (including aspirin) within 14 days prior to randomization, β adrenergic receptor agonists or blockers, strong CYP3A inhibitors, or nonpotassium sparing diuretics (e.g., loop or thiazide diuretics) within 28 days prior to randomization; 12. Used tricyclic antidepressants or monoamine oxidase inhibitor medications within 14 days prior to randomization; 13. Unlikely or unable to adhere to the study visit schedule or comply with protocol procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety as measured by number of subjects with adverse events. | 12 weeks (Baseline through 4 weeks post last dose) | — |
| Safety as measured by the number of subjects with abnormal post baseline shifts in laboratory results. | 12 weeks (Baseline through 4 weeks post last dose) | — |
| Change from baseline in the patient reported submental bulging scale. | 12 weeks (Baseline through 4 weeks post last dose) | The self-rating scale is 5-point scale that the subject evaluates their submental fat. |
| Change from baseline in the clinician reported submental bulging scale | 12 weeks (Baseline through 4 weeks post last dose) | The clinician scale is 5-point rating scale in which the clinician evaluates the subject's submental fat. |
| Change in submental fat thickness measured with calipers (mm). | 12 weeks (Baseline through 4 weeks post last dose) | — |
Countries
United States
Outcome results
None listed